Učitavanje...

[(89)Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study

Recent studies on immune-mediated inflammatory lung diseases show encouraging treatment results with rituximab, a monoclonal antibody (mAb) against CD20-expressing B lymphocytes. The present pilot study aimed to explore the possibility to image CD20-expression in the lungs as future early predictor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am J Nucl Med Mol Imaging
Glavni autori: Adams, Human, van de Garde, Ewoudt MW, van Moorsel, Coline HM, Vugts, Danielle J, van Dongen, Guus AMS, Grutters, Jan C, Keijsers, Ruth G
Format: Artigo
Jezik:Inglês
Izdano: e-Century Publishing Corporation 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6971479/
https://ncbi.nlm.nih.gov/pubmed/31976159
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!